VACH
Voyager Acquisition Corp.
$2.14
+0.09
(+4.39%)
Mkt Cap
67.68M
Volume
211,475
52W Range
1.72-27.36
Sector
Financial Services
Beta
-0.37
EPS (TTM)
0.25
P/E Ratio
8.62
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Voyager Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to target the healthcare and healthcare-related industries.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Net Income | 8.99M | 4.14M |
| EPS | 0.36 | 0.15 |
| Free Cash Flow | (486,182) | (703,468) |
| FCF / Share | -0.02 | -0.03 |
| Operating CF | (486,182) | (703,468) |
| Total Assets | 270.06M | 259.81M |
| Total Debt | 0 | 0 |
| Cash & Equiv | 182,103 | 668,285 |
| Book Value | 256.72M | 247.73M |
| Return on Equity | 0.04 | 0.02 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 180,498 | 1.71M | 2.36M | 2.49M | 2.43M | 2.92M | 1.32M | (50,808) | (52,040) |
| EPS | 0.01 | 0.07 | 0.09 | 0.08 | 0.10 | 0.09 | 0.07 | -0.00 | -0.00 |
| Free Cash Flow | (149,313) | (70,247) | 159,856 | 1.63M | (2.21M) | (89,609) | (613,859) | 0 | 0 |
| FCF / Share | -0.01 | -0.00 | 0.01 | 0.05 | -0.09 | -0.00 | -0.03 | N/A | N/A |
| Operating CF | (149,313) | (70,247) | 159,856 | 1.63M | (2.21M) | (89,609) | (613,859) | 0 | 0 |
| Total Assets | 272.28M | 270.06M | 267.55M | 264.82M | 262.29M | 259.81M | 256.88M | 392,381 | 236,955 |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 32,790 | 182,103 | 252,350 | 92,494 | 445,492 | 668,285 | 757,895 | 25,000 | 25,000 |
| Book Value | (14.45M) | 256.72M | 255.01M | 252.65M | 250.16M | 247.73M | 244.81M | (82,848) | (32,040) |
| Return on Equity | N/A | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | N/A | N/A |
VACH News
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
Crossingbridge Advisors LLC Acquires Shares of 46,779 Voyager Acquisition Corp. $VACH
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.